tiprankstipranks
1st Group Ltd. (AU:VFX)
ASX:VFX
Australian Market
Want to see AU:VFX full AI Analyst Report?

1st Group Ltd. (VFX) AI Stock Analysis

3 Followers

Top Page

AU:VFX

1st Group Ltd.

(Sydney:VFX)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
AU$0.06
▼(-41.00% Downside)
Action:Reiterated
Date:06/27/26
The score is driven down primarily by weak financial performance (losses, negative equity, and ongoing cash burn). Technicals provide partial support with price above key moving averages, but momentum indicators are mixed. Valuation remains challenged due to a negative P/E and no dividend yield data.
Positive Factors
Revenue Growth Upside
A material revenue jump in 2025 shows the business can win customers and scale top-line activity. Over a 2-6 month horizon this supports revenue momentum and provides a foundation for future margin improvement if cost discipline and unit economics are addressed.
Negative Factors
Negative Shareholder Equity
Consistently negative equity is a structural capital issue that limits the company's ability to absorb losses and invest. Over months this increases reliance on external funding, raises dilution risk, and constrains strategic options like M&A or material R&D investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Upside
A material revenue jump in 2025 shows the business can win customers and scale top-line activity. Over a 2-6 month horizon this supports revenue momentum and provides a foundation for future margin improvement if cost discipline and unit economics are addressed.
Read all positive factors

1st Group Ltd. (VFX) vs. iShares MSCI Australia ETF (EWA)

1st Group Ltd. Business Overview & Revenue Model

Company Description
Operating in Australia, Visionflex Group Limited and its associated companies specialize in providing cutting-edge healthcare, telehealth, and remote diagnostic services. The company's portfolio features virtual healthcare systems and specialized ...
How the Company Makes Money
null...

1st Group Ltd. Financial Statement Overview

Summary
Financial health is high risk: profitability is weak and worsening with deep operating/net losses, shareholder equity is negative across periods (limited flexibility and higher funding dependence), and operating/free cash flow remain negative (ongoing cash burn). Debt improved in 2025 and free cash flow was less negative year over year, but the business is still not self-funding.
Income Statement
14
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
BreakdownJun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue4.19M6.65M4.47M4.83M
Gross Profit-2.42M3.94M3.41M4.83M
EBITDA-3.37M-1.32M-3.56M-6.43M
Net Income-3.19M-1.83M-3.66M-6.82M
Balance Sheet
Total Assets3.39M2.88M4.09M4.27M
Cash, Cash Equivalents and Short-Term Investments1.89M1.16M1.44M2.01M
Total Debt2.47M13.65M12.11M4.65M
Total Liabilities5.22M19.76M18.73M8.16M
Stockholders Equity-1.82M-8.11M-6.74M-3.89M
Cash Flow
Free Cash Flow-3.19M-1.38M-3.68M-2.82M
Operating Cash Flow-3.16M0.000.000.00
Investing Cash Flow-29.51K276.80K720.13K-21.84K
Financing Cash Flow3.92M798.81K2.36M4.59M

1st Group Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
AU$5.20M-1.19245.46%-5.32%72.83%
46
Neutral
AU$11.34M-1.66-218.76%76.94%42.95%
42
Neutral
AU$6.05M-0.63152.58%-57.91%-9.02%
41
Neutral
AU$3.47M63.5015.41%-5.76%8.00%
41
Neutral
AU$7.05M-2.30-44.35%-32.09%34.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:VFX
1st Group Ltd.
0.06
-0.02
-21.05%
AU:GLH
Global Health Limited
0.06
>-0.01
-13.24%
AU:EVE
EVE Health Group Limited
0.02
>-0.01
-33.33%
AU:CMB
Regeneus Ltd.
0.42
0.21
97.62%
AU:HIQ
HitIQ Limited
0.01
>-0.01
-28.57%

1st Group Ltd. Corporate Events

Visionflex Wins NSW Health Contract for Statewide Remote Monitoring Hardware
Jun 25, 2026
Visionflex Group Limited has secured an approximately $0.8 million contract with NSW Health to supply proprietary clinical hardware for the state’s Remote Patient Monitoring Digital Uplift program, supporting Virtual Hospital and Hospital in...
Visionflex Quarterly Cash Flow Shows Ongoing Operating Outflows
Apr 28, 2026
Visionflex Group Limited reported cash receipts from customers of A$778,000 for the March 2026 quarter, against operating outflows driven mainly by staff wages, administration, and manufacturing costs, resulting in negative operating cash flow of ...
Visionflex Performance Rights Lapse Trims Future Equity Pool
Mar 31, 2026
Visionflex Group Limited has disclosed that 280,000 performance rights, trading under the ASX code VFXAR, have lapsed as of March 31, 2026, after the relevant vesting conditions were not met or were deemed incapable of being satisfied. The cessati...
Visionflex Seeks ASX Quotation for 44,444 New Ordinary Shares
Mar 31, 2026
Visionflex Group Limited has applied for quotation on the ASX of 44,444 new fully paid ordinary shares, to be issued on 31 March 2026 under the code VFX. The shares arise from the exercise or conversion of existing options or other convertible sec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2026